Clinical Trial Update: Palbociclib With Everolimus + Exemestane In BC [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating palbociclib in combination with everolimus and exemestane in HER2-negative, HR-positive breast cancer has completed with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Everolimus (everolimus)
• Exemestane (Exemestane)
• Palbociclib (palbociclib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor (HR)-Positive Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-08-29